Axogen Closes $200M BioCircuit Acquisition, Adds $34M 2027 Revenue Guidance
AXGN has more than doubled off its 52-week low of $15.27.
Summary
Axogen completed its $200M acquisition of BioCircuit Technologies, adding the first FDA-cleared sutureless nerve repair device and providing new revenue contribution guidance of $6M for Q4 2026 and $34M for 2027.
Key Events · M&A and Partnerships · AXGN
-
Acquisition Completed
The $200 million cash acquisition of BioCircuit Technologies has closed, adding NerveTape, the first FDA-cleared sutureless device for peripheral nerve repair, to Axogen's portfolio.
-
New Revenue Guidance
BioCircuit is expected to contribute approximately $6 million to Q4 2026 revenue and $34 million to 2027 revenue, figures not previously included in Axogen's full-year guidance of at least 24% growth.
-
Margin and Cash Flow Reaffirmed
Management continues to expect gross margin of at least 73% and to be free cash positive for full-year 2026.
-
Strategic Fit
NerveTape aligns with Axogen's direct sales organization and hospital contracting capabilities, expanding its addressable market in peripheral nerve repair.
Analysis · AXGN · Industrial Applications And Services
The $200 million acquisition of BioCircuit Technologies is now complete, bringing NerveTape — the first FDA-cleared sutureless peripheral nerve repair device — into Axogen's portfolio. While the deal was announced three weeks ago, this filing reveals new financial specifics: BioCircuit is expected to contribute approximately $6 million to Q4 2026 revenue and $34 million to 2027 revenue, figures that were not included in Axogen's prior full-year guidance of at least 24% growth. Management also reaffirmed gross margin of at least 73% and free cash flow positivity for 2026. The acquisition expands Axogen's addressable market in peripheral nerve repair and leverages its existing direct sales organization.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.4% of the 1487 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AXGN was trading at $39.92 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $15.27 to $52.91. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.